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doi:10.1Objective: Since the introduction of the cut-and-sew Cox maze procedure for atrial fibrillation, there has been
substantial innovation in techniques for ablation. Use of alternative energy sources for ablation simplified the
procedure and has resulted in dramatic increase in the number of patients with atrial fibrillation treated by
surgical ablation. Despite its increasingly widespread adoption, there is lack of rigorous clinical evidence to
establish this procedure as an effective clinical therapy.
Methods: This article describes a comparative effectiveness randomized trial, supported by the Cardiothoracic
Surgical Clinical Trials Network, of surgical ablation with left atrial appendage closure versus left atrial append-
age closure alone in patients with persistent and long-standing persistent atrial fibrillation undergoing mitral
valve surgery. Nested within this trial is a further randomized comparison of 2 different lesions sets: pulmonary
vein isolation and the full maze lesion set.
Results: This article addresses trial design challenges, including how best to characterize the target population,
operationalize freedom from atrial fibrillation as a primary end point, account for the impact of antiarrhythmic
drugs, and measure and analyze secondary end points, such as postoperative atrial fibrillation load.
Conclusions: This article concludes by discussing how insights that emerge from this trial may affect surgical
practice and guide future research in this area. (J Thorac Cardiovasc Surg 2011;142:257-64)Supplemental material is available online.
Atrial fibrillation (AF) coexists in 50% of patients present-
ing for mitral valve surgery (MVS), and in at least half of
these patients this dysrhythmia has been long-standinge Department of Thoracic and Cardiovascular Surgery,a Cleveland Clinic,
land, Ohio; the Division of Cardiothoracic Surgery,b Columbia University
cal Center, New York, NY; the International Center for Health Outcomes
nnovation Research (InCHOIR) in the Department of Health Evidence and
y,c Mount Sinai School of Medicine, New York, NY; the Department of Car-
scular and Thoracic Surgery,d Montefiore-Einstein Heart Center, New York,
he Division of Thoracic and Cardiovascular Surgery,e University of Virginia,
ottesville, Va; the Department of Cardiovascular Sciences,f East Carolina
Institute at East Carolina University, Greenville, NC; the Department of
ry,g Montreal Heart Institute, University of Montreal, Montreal, Quebec,
da; the Division of Cardiovascular Sciencesh and Office of Biostatistics
rch,i National Heart, Lung and Blood Institute, Bethesda, Md; and the Divi-
f Cardiovascular Surgery,j University of Pennsylvania, Philadelphia, Pa.
ed by the National Heart, Lung and Blood Institute, the Canadian Institute of
h Research, and the National Institute of Neurological Diseases and Stroke.
d for publication March 4, 2011; revisions receivedMarch 25, 2011; accepted
blication April 11, 2011; available ahead of print May 26, 2011.
for reprints: Annetine C. Gelijns, PhD, InCHOIR, Department of Health
nce and Policy, Mount Sinai School ofMedicine, One Gustave L. Levy Place,
077, New York, NY 10029 (E-mail: annetine.gelijns@mssm.edu).
23/$36.00
ht 2011 Published by Elsevier Inc. on behalf of The American Association
racic Surgery
016/j.jtcvs.2011.04.010
The Journal of Thoracic and Caand refractory to medical treatment (persistent or long-
standing persistent, in current consensus terminology).1
The rhythm is presumed to relate to left atrial enlargement
from the valvular heart disease. Preoperative AF is associ-
ated with reduced postoperative survival and increased
risk of stroke. The cut-and-sew Cox maze procedure—
introduced in the late 1980s—provided surgeons with
a therapeutic approach to help restore sinus rhythm and
avert the mortality and morbidity associated with this
disease.2,3 Despite the reported success of this procedure,
its complexity initially prevented widespread adoption.
The more recent development of tissue ablation technologies
and alternative energy sources, however, has simplified the
technique and significantly reduced operative time. These
improvements have led to substantial growth in the number of
procedures performed.
Despite this increased adoption, there is lack of rigorous
clinical evidence to establish surgical ablation as an effective
clinical therapy. Most available studies have been retrospec-
tive, conducted in single centers, and not rigorously con-
trolled. Although 9 randomized trials4-12 have compared
the benefits of added ablation surgery with those of MVS
alone, most of these had sample sizes insufficient to draw
definitive conclusions, and none enrolled more than 100
patients. Moreover, both randomized and nonrandomized
studies have been characterized by significant variations inrdiovascular Surgery c Volume 142, Number 2 257
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CTSN ¼ Cardiothoracic Surgical Clinical Trials
Network
FDA ¼ Food and Drug Administration
LAA ¼ left atrial appendage
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PVI ¼ pulmonary vein isolation
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and variations in definition and measurement of the
primary end point. Furthermore, few studies included the
full gamut of relevant clinical end points. A recent meta-
analysis of 5 trials that used freedom from AF within 12
months as a primary end point in patients with nonparoxys-
mal AF found that surgical ablation greatly increased the
odds of being free from AF at 12 months, but the odds ratios
had wide confidence intervals and were derived from trials
that had considerable heterogeneity in their designs.13 As
such, large-scale trials are needed to provide better evidence
for guiding physician and patient decision making.
The need for such evidence is highlighted by 2 recent
developments. First, the Comparison of Rate Control and
Rhythm Control in Patients With Recurrent Persistent
Atrial Fibrillation (RACE) trial found that treatment with
antiarrhythmic drugs with the intent to restore normal sinus
rhythm did not improve survival or reduce stroke risk rela-
tive to the simpler strategy of pharmacologic rate control in
patients with persistent AF, thus casting doubts on the ben-
efits of restoring sinus rhythm.14 Second, the Percutaneous
Left Atrial Appendage Closure versus Warfarin for Stroke
Prevention in Atrial Fibrillation Patients (PROTECT AF)
trial, which evaluated percutaneous closure of the left atrial
appendage (LAA) in patients with nonvalvular AF at ele-
vated risk of stroke, found that the efficacy of LAA closure
was not inferior to standard therapy with warfarin sodium.15
These trials raise the question of whether LAA closure with
rate control alone would be sufficient in a population with
AF and mitral valve disease. Only 1 of the randomized trials
on ablation therapy in patients undergoing MVS used LAA
closure in both treatment arms. An important outstanding
question is whetherMVSwith LAA closure alone is a viable
treatment option relative to surgical ablation.
This article describes a comparative effectiveness ran-
domized trial of surgical ablation with LAA closure versus
LAA closure alone in patients with persistent and long-
standing persistent AF undergoing MVS. This trial has
been designed and is conducted within the Cardiothoracic
Surgical Clinical Trials Network (CTSN), which is sup-
ported by the National Heart, Lung and Blood Institute,
the National Institute of Neurological Disorders and258 The Journal of Thoracic and Cardiovascular SurgStroke, and the Canadian Institutes for Health Research
(Appendix 1). Nested within this trial is a further random-
ized comparison of 2 different lesions sets. This article
addresses trial design challenges, including how best to
characterize the target population, operationalize freedom
from AF as a primary end point, account for the effects of
antiarrhythmic drugs, and measure and analyze secondary
end points, such as postoperative AF load. This article
concludes by discussing how insights that emerge from
this trial may affect surgical practice and guide future
research in this area.
CHARACTERIZATION OF TARGET POPULATION
Surgical ablation does not yet have a clear-cut role as
a stand-alone procedure, and the obvious population for
evaluating this procedure is patients undergoing concomi-
tant cardiac surgery. This CTSN trial, therefore, focuses
on adult patients undergoing MVS for several reasons. It
is the most common indication among concomitant proce-
dures; around 50% of patients undergoing MVS with AF
also undergo an ablation procedure.1 Patients who remain
in AF after MVS have lower survival than do those in sinus
rhythm. Moreover, because the left atrium is routinely
opened for MVS, ablation adds little time or risk to the sur-
gical procedure; the surgeon is ‘‘already there’’ for the mi-
tral valve procedure. The protocol targets adult patients
with a clinical indication for surgery for the following: or-
ganic mitral valve disease, functional nonischemic mitral
regurgitation, or ischemic mitral regurgitation with evi-
dence of concomitant structural mitral valve disease. The
rationale for defining the target population in this manner
is to avoid competition for patients who would qualify for
2 other CTSN trials that enroll patients with severe and
moderate ischemic mitral regurgitation (both the latter pro-
tocols exclude patients with structural valvular disease).
DEFINING AF
Interpretation of the current literature on surgical ablation
is challenging, in part because of varying and inconsistent
terminology used to describe the pattern and chronicity of
AF. Traditionally, studies used continuous and intermittent
labels, proposed by Cox,2 where continuous AF is defined
as AF that does not self-terminate and intermittent AF as
any AF that self-terminates but may be recurrent. To facili-
tate comparison of outcomes across trials, we adopted the
classification from the 2001 Expert Consensus Statement
on Catheter and Surgical Ablation of Atrial Fibrillation.16
Persistent AF is defined as AF that is not self-terminating
and lasts longer than 7 days, or that lasts less than 7 days
with the necessity for pharmacologic or electrical cardiover-
sion. Long-standing persistent AF is defined as continuous
AF longer than 1 year in duration. This definition applies
only to AF episodes that are at least 30 seconds in duration
and do not have a reversible cause, such as acute pulmonaryery c August 2011
FIGURE 1. Atrial fibrillation (AF) trial design. MVS, Mitral valve
surgery.
FIGURE 2. Pulmonary vein isolation lesion set with bipolar device.
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3 months and is paroxysmal, MVS results in conversion to
sinus rhythm approximately 80% of the time. By choosing
patients with persistent or long-standing persistent AF, we
have excluded those patients who move between AF and si-
nus rhythm sporadically and without intervention, enabling
us to attribute elimination of AF to the assigned treatment.
Another critical consideration in trial design is ensuring
that the eligibility criteria do not unnecessarily restrict re-
cruitment of patients. To assess the available patient popu-
lation and highlight those eligibility criteria that may have
a major impact on enrollment, CTSN investigators used
detailed prospective screening logs. On the basis of these
data, eligibility criteria were streamlined, and the protocol
no longer excludes patients needing concomitant surgical
management of functional tricuspid regurgitation, patent fo-
ramen ovale, coronary artery bypass grafting, and aortic
arch or aortic valve procedures (Appendix 2).
TREATMENTARMS
At the induction of anesthesia, patients are randomly al-
located in a 1:1 fashion to surgical ablation with LAA clo-
sure or to LAA closure alone. Nested within this trial is
a further randomized comparison within the ablation arm
of 2 different lesions sets: pulmonary vein isolation (PVI)
versus a biatrial lesion set patterned after the Cox maze
III procedure (Figure 1). Random allocation of lesion setThe Journal of Thoracic and Cais performed intraoperatively after verification of the ab-
sence of left atrial thrombus by transesophageal
echocardiography.
An important issue in trial design, especially with com-
plex surgical procedures, is standardization of treatment in-
terventions. Such standardization removes a potentially
large source of random variation and thereby improves
the efficiency of design and precision of trial results. The
CTSN investigators developed treatment guidelines
(Appendix E1), which include a pacing protocol (before
and after PVI) to confirm acute conduction block at the pul-
monary vein level. To date, none of the studies in the liter-
ature has assessed acute procedural success (conduction
block). Bipolar energy sources are preferred for PVI alone
and for the PVI component of the biatrial maze lesion set.
For PVI, 2 separate encircling lesions are made around
left and right pulmonary veins (Figure 2). For PVI with uni-
polar energy sources, a box lesion are made, consisting of
a continuous ablation line around all 4 pulmonary veins. Af-
ter PVI, the heart is arrested, and the LAA is excised or ex-
cluded. The remainder of the procedure for patients
randomly allocated to the biatrial maze lesion set is per-
formed at a point in the operation dictated by the surgeon’s
standard practice.
In recent years, several energy sources for ablation have
been introduced into clinical practice. There do not appear
to be significant differences in efficacy or safety of different
energy sources. Radiofrequency is the oldest energy source
with the largest clinical experience; thus results from any
trial that does not incorporate radiofrequency ablation may
lack generalizability to the broader surgical community. In
this trial, we limited the devices to those based on a radiofre-
quency energy source. In addition to the linear lesions cre-
ated by unipolar or bipolar radiofrequency, additional spot
lesions will be created at the mitral annulus and isthmus
with either unipolar radiofrequency or cryotherapy.
Closure (amputation) of the LAA may be achieved by
cut-and-sew technique or by application of a surgicalrdiovascular Surgery c Volume 142, Number 2 259
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class I or III antiarrhythmic drugs beginning within 24 hours
of surgery, with drug therapy to be terminated at 3 months.
Warfarin sodium is prescribed for patients in both arms
throughout the follow-up period.
DEFINING SUCCESS IN ABLATION TRIALS:
ESTABLISHING A PRIMARY END POINT
The primary efficacy end point is freedom from AF as-
sessed by 3-day continuous Holter monitoring at 6 and 12
months after ablation. Freedom from postoperative AF is
defined as absence of any episode of AF lasting longer
than 30 seconds at both 6- and 12-month monitoring time
points. The null hypothesis is that there is no difference in
the proportion of patients meeting the primary outcome be-
tween patients randomly allocated to surgical ablation plus
LAA closure or to LAA closure alone. The primary null hy-
pothesis is tested in an intent-to-treat analysis with a .05
level Mantel-Haenszel c2 test with stratification by clinical
center, the factor on which randomization is stratified. For
simplicity, the benefit of ablation between treatment arms
is quantified as a simple difference in the proportion of pa-
tients free of AF in the 2 groups (expressed as a relative risk
with associated 95% confidence intervals).
Patients who die before the 12-month assessment or who
are determined by an independent adjudicator to be too ill to
undergo AF assessment are considered to have treatment
failure. In the primary analysis, patients in both treatment
arms who undergo ablation therapy for AF (including surgi-
cal ablation or percutaneous catheter ablation) after the in-
dex procedure are considered to have treatment failure. The
trial incorporates a 3-month blanking period from the time
of randomization, which allows time for recovery from the
inflammatory effects of the ablation. Events that occur dur-
ing this period are not taken into account in the primary
efficacy analysis. In the primary analysis, the use of antiar-
rhythmic drugs after the first 3 months is not considered
a treatment failure, because the trial is not able to standard-
ize the use of antiarrhythmic drugs by referring cardiolo-
gists during the follow-up period.
SAMPLE SIZE ESTIMATION
Sample size estimates must be based on data from the
clinical literature and the ability to detect, with high proba-
bility, a clinicallymeaningful presumed benefit of treatment.
The reported absence ofAF 1 year afterMVS among control
patients in previously executed randomized clinical trials
ranges from approximately 15% to 35%. These trials all re-
ported a relatively large but imprecise benefit of ablation.
For example, Doukas and colleagues10 found an absolute
benefit of 35% for ablation in the proportion of patients
free of AF at 1 year (95% confidence interval 17%–
53%), corresponding to a slightly more than 3-fold increase
in the proportion of patients free of AF at 1 year.260 The Journal of Thoracic and Cardiovascular SurgFor a primary end point assessing freedom from AF at
both 6 months and 1 year, we assume that 25% of patients
treated with MVS and LAA closure will be free of AF. A
total of 260 patients (130 in each group) provides 90%
power to detect an absolute increase of 20% (25% vs
45%) in the proportion of patients free of AF according
to a 2-tailed .05 level continuity-corrected c2 test. The
sample size takes into account a single interim analysis in
addition to the final analysis. The interim analysis will
take place when 50% of patients have been followed up
for 1 year and will be conducted at the .003 significance
level. The results will be reported only to an independent
data and safety monitoring board, which will assess whether
the trial should stop early if the results favor either treat-
ment. The final analysis will be conducted at the .049 signif-
icance level. The data and safety monitoring board will also
monitor for futility; that is, they will recommend stopping
the trial if the probability of detecting an absolute 20% ben-
efit for those randomly allocated to MVS plus ablation is
less than 20%. Thus, it is possible to carry out a well-
designed, prospective clinical trial with a relatively small
sample size given the anticipated difference in freedom
from AF between the 2 study arms.
AF SECONDARY END POINTS
Designing end points to capture response to treatment in
this trial requires an understanding of the episodic nature of
AF and the need for rigorous evaluation of postoperative
rhythm status. In addition to Holter monitoring at 6 and
12 months, this trial uses transtelephonic monitoring tech-
nology to obtain electrocardiographic data from weekly
rhythm strips (90 seconds) to assess rhythm activity better
during the interval periods. The downside to weekly trans-
telephonic monitoring is that it (1) requires a higher level
of compliance from patients, (2) requires patient education
on the use of such devices, and (3) requires consistency in
timing of patient transmission to avoid bias from circadian
rhythm. As such, this modality of rhythm assessment is
probably not reliable enough for use as the primary end
point. After the design of the current trial, the Food and
Drug Administration (FDA) approved an implantable con-
tinuous rhythm monitoring device, which the CTSN is
now considering for use in a substudy.
AF Burden
One end point that arises from the use of more frequent
rhythm monitoring is AF load, which is defined as the pro-
portion of recordings documenting AF in a given patient
during spot recordings. Here patients are required to sub-
mit rhythm strips on a regular basis from 3 months after
surgery until the time of the primary end point assessment.
Although this method places greater burden on patients
and can result in noncompliance, this form of analysis pre-
vents any single arrhythmia from significantly affectingery c August 2011
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mias encountered is examined at the conclusion of the
study.
Freedom From Any Electrocardiographically
Documented Atrial Tachyarrhythmia Recurrences
In addition to AF load, another secondary end point of
interest is freedom from any electrocardiographically
documented atrial tachyarrhythmia recurrences. Although
the primary interest is the success of AF ablation, there exists
the possibility for induction of other arrhythmias during the
process. Freedom fromAF, atrial flutter, or atrial tachycardia
will be definedbyabsenceof anyof these electrocardiograph-
ically documented events lasting longer than 30 seconds.
ADDITIONAL CLINICAL SECONDARY END
POINTS
Whereas the impact on the occurrence of AF episodes is
important to patients, mortality, important adverse events
such as stroke, and quality of life are critical for defining
the value of a therapy. Although these events themselves
have profound effects on patients and their families, their
frequencies are low, and evaluating the effect of therapy
on survival or stroke as a primary end point with precision
would require extremely large sample sizes.
We therefore have included a composite primary safety end
point,which is defined as a composite of death, stroke, serious
cardiac adverse events, cardiac rehospitalizations, transient
ischemic attack, pulmonary embolism, peripheral embolism,
excessive bleeding, deep sternal wound infection ormediasti-
nitis, damage to specialized conduction system requiring per-
manent pacemaker, and damage to peripheral structures, such
as the esophagus, within 30 days after the procedure or hospi-
tal discharge (whichever is later). In addition, secondary end
points include assessing major adverse cardiac and cerebro-
vascular events, which is relevant to cardiac procedures in
general, defined as a non-weighted composite score of death,
stroke, worsening heart failure (þ1 New York Heart Associa-
tion functional class); hospitalization for congestive heart
failure; and mitral valve reintervention within 12 months of
randomization. Survival and differences in the incidence of
serious adverse events within 12 months of randomization
are also compared between groups with Poisson regression
(with exact 95% confidence intervals).
In addition to looking at events that are life threatening or
life altering, we measure overall impact on quality of life
and hospitalization burden. The long-term impact on qual-
ity of life is assessed at 12 months and includes a general
health status measure (Short Form-12) and a disease-
specific measure (the Atrial Fibrillation Severity Scale).
All hospitalization readmissions and total hospital days
are measured throughout the duration of follow-up, which
is 2 years to assess long-term clinical end points.The Journal of Thoracic and CaDISCUSSION
The prevalence of AF among patients with mitral valve
disease presenting for surgery and the development of new
ablation techniques that have simplified the cut-and-sew
maze technique have led to renewed interest in surgical ab-
lation. Subsequently, questions have emerged as to whether
the results from the PROTECT AF trial, which showed
equivalence of LAA closure to warfarin sodium in patients
with nonvalvular AF, would be applicable to patients with
(long-standing) persistent AF undergoing MVS. What then
would be the value of surgical ablation and LAA closure rel-
ative to excision of the LAA alone in this patient group?
The current literature provides insufficient evidence to ad-
dress this important clinical issue. Among the numerous de-
vice technologies to enter the clinical arena for treatment of
AF, only devices using cryoablation have been specifically
approved by the FDA for the treatment ofAF. The remaining
energy sources (radiofrequency, laser,microwave, and ultra-
sound) have been approved for the ablation of cardiac tissue
but not specifically for AF therapy. Clinical trials evaluating
the efficacy of these devices for this indication are nowunder
way, but none of these trials provide a randomized compar-
ison to MVS with LAA closure alone. Clearly, surgical ab-
lation procedures have been extensively used in practice
and have been the subject of evaluative research. The litera-
ture evaluating the effectiveness of surgical ablation as
a therapeutic approach is difficult to interpret, however, be-
cause of the paucity of rigorously controlled studies and the
lack of standardization in procedures, AF classification
schemes, and primary end points. The paucity of rigorous
clinical evidence regarding the effectiveness of surgical ab-
lation, the fact that nearly half of the patients undergoing
MVS do not undergo a concomitant surgical ablation proce-
dure, and recent evidence that LAA closure is not inferior to
anticoagulation in a nonvalvular patient group support the
argument that there is equipoise to design a trial in patients
with (long-standing) persistent AF that compares ablation
and LAA closure with LAA closure alone.
TheCTSNhas designed and is conducting such a compar-
ative effectiveness trial, which requires different manufac-
turers to support an FDA investigational device exemption
application. This trial design, however, is geared toward
evaluation of ablation as a therapeutic approach (not
a specific device) and will not support FDA approval for
any individual device.
The results from this trial will provide several important
insights. First, it will offer evidence regarding the compar-
ative benefits of surgical ablation. An open question re-
mains how best to assess benefit in ablation trials, given
the episodic nature of this disease. There is currently no ac-
cepted standard for defining a successful surgical ablation
procedure, and the variations in primary end points have
led to difficulty in interpreting the current literature. Somerdiovascular Surgery c Volume 142, Number 2 261
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end point, with standard Kaplan-Meier methods for analy-
sis, which may be more appropriate for sustained clinical
events such as stroke or death.17 Rhythm status and freedom
from AF represent clinical states with intermittent occur-
rences, thereby rendering the first occurrence less relevant.
When AF is detected on an electrocardiogram, the time of
detection does not necessarily represent the time that the
arrhythmia began, and time-to-event methods are thus less
appropriate. Freedom from AF during the first year has
become increasingly used as a primary end point. In some
trials, success is defined only as freedom fromAF at a single
postoperative time point (eg, 3 months), whereas in others,
a successful outcome requires documentation of normal
rhythm that is sustained for a specific period, or success is
defined more stringently as absence of AF after discontinu-
ation of all antiarrhythmic drugs. In this trial, AF is
measured by 3-day continuous monitoring at 6 and 12
months after ablation, and freedom from AF is defined by
absence of AF (lasting>30 seconds) at both time points.
This trial will also provide important information on
survival, safety, quality of life, functional status, and hospi-
talization time to help guide treatment decisions.
In addition to providing evidence for making treatment
decisions, this trial will generate insights to help shape fu-
ture clinical research. For example, if ablation is found to
offer better AF control than LAA closure alone, the nested
subcomparison of different lesion sets will provide prelim-
inary data to inform the design of subsequent trials compar-
ing specific lesion sets and ablation devices. Moreover, the
trial compares 2 techniques for postablation heart rhythm
monitoring (long-term Holter monitoring vs weekly rhythm
strips), which should provide the evidence needed to deter-
mine optimal methods for evaluating postoperative rhythm
control in the context of a clinical trial. Because more
frequent rhythm assessment may reveal otherwise
unappreciated episodes of AF, this comparison may also
redefine the general definition of freedom from AF, thereby
affecting clinical decision-making algorithms (such as
those used for anticoagulation). The CTSN investigators
are also designing a substudy that includes an implantable
monitoring device. Finally, current methods to analyze lon-
gitudinal data for complex temporal patterns seen in AF are
limited, and so, as mentioned, they are the subject of
methodologic exploration by the investigators. A rigorous
evidence basis for surgical ablation therapies for persistent
or long-standing persistent AF ablation is much needed.
This comparative effectiveness trial should provide an
important first step in achieving that goal.
References
1. Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB,
O’Brien SM, Griffith BP, Peterson ED. Atrial fibrillation correction surgery:
lessons from the Society of Thoracic Surgeons National Cardiac Database.
Ann Thorac Surg. 2008;85:909-14.262 The Journal of Thoracic and Cardiovascular Surg2. Cox JL. Cardiac surgery for arrhythmias. J Cardiovasc Electrophysiol. 2004;15:
250-62.
3. Cox JL. The longstanding persistent confusion surrounding surgery for atrial
fibrillation. J Thorac Cardiovasc Surg. 2010;139:1374-86.
4. Khargi K, Deneke T, Haardt H, Lemke B, Grewe P, M€uller KM, et al. Saline-ir-
rigated, cooled-tip radiofrequency ablation is an effective technique to perform
the maze procedure. Ann Thorac Surg. 2001;72:S1090-5.
5. Jessurun ER, van Hemel NM, Defauw JJ, Brutel De La Riviere A, Stofmeel MA,
et al. A randomized study of combining maze surgery for atrial fibrillation with
mitral valve surgery. J Cardiovasc Surg (Torino). 2003;44:9-18.
6. Akpinar B, Gulden M, Sagbas E, Sanisoglu I, Ozbek U, Caynak B, et al. Com-
bined radiofrequency modified maze and mitral valve procedure through a port
access approach: early and mid term results. Eur J Cardiothorac Surg. 2003;
24:223-30.
7. Schuetz A, Schulze CJ, Sarvanakis KK,Mair H, Plazer H, Kilger E, et al. Surgical
treatment of permanent atrial fibrillation using microwave energy ablation: a pro-
spective randomized clinical trial. Eur J Cardiothorac Surg. 2003;24:475-80.
8. Vasconcelos JT, Scanavacca MI, Sampaio RO, Grinberg M, Sosa EA,
Oliveira SA. Surgical treatment of atrial fibrillation through isolation of the
left atrial posterior wall in patients with chronic rheumatic mitral valve disease.
A randomized study with control group. Arq Bras Cardiol. 2004;83:211-8.
203-10. English, Portuguese.
9. de Lima GG, Kalil RA, Leiria TL, Hatem DM, Kruse CL, Abrah~ao R, et al.
Randomized study of surgery for patients with permanent atrial fibrillation as
a result of mitral valve disease. Ann Thorac Surg. 2004;77:2089-95.
10. Doukas G, Samani NJ, Alexiou C, Oc M, Chin DT, Stafford PG, et al. Left atrial
radiofrequency ablation during mitral valve surgery for continuous atrial fibrilla-
tion: a randomized controlled trial. JAMA. 2005;294:2323-9.
11. Abreu Filho CA, Lisboa LA, Dallan LA, Spina GS, Grinberg M, Scanavacca M,
et al. Effectiveness of the maze procedure using cooled-tip radiofrequency
ablation in patients with permanent atrial fibrillation and rheumatic mitral valve
disease. Circulation. 2005;112(9 Suppl):120-5.
12. Blomstr€om-Lundqvist C, Johansson B, Berglin E, Nilsson L, Jensen SM,
Thelin S, et al. A randomized double-blind study of epicardial left atrial
cryoablation for permanent atrial fibrillation in patients undergoing mitral valve
surgery: The SWEDish Multicentre Atrial Fibrillation Study (SWEDMAF). Eur
Heart J. 2007;28:2902-8.
13. Kong MH, Lopes RD, Piccini JP, Hasselblad V, Bahnson TD, Al-Khatib SM.
Surgical maze procedure as a treatment for atrial fibrillation: a meta-analysis
of randomized controlled trials. Cardiovasc Ther. 2010;28:311-26.
14. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A
comparison of rate control and rhythm control in patients with recurrent persis-
tent atrial fibrillation. N Engl J Med. 2002;347:1834-40.
15. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Per-
cutaneous closure of the left atrial appendage versus warfarin therapy for preven-
tion of stroke in patients with atrial fibrillation: a randomized non-inferiority
trial. Lancet. 2009;374:534-42. Erratum in: Lancet. 2009;374:1596.
16. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/
AHA/ESC guidelines for the management of patients with atrial fibrillation: ex-
ecutive summary. A Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the European Society
of Cardiology Committee for Practice Guidelines and Policy Conferences (Com-
mittee to Develop Guidelines for the Management of Patients With Atrial Fibril-
lation): developed in Collaboration With the North American Society of Pacing
and Electrophysiology. J Am Coll Cardiol. 2001;38:1231-66.
17. Camm AJ, Reiffel JA. Defining endpoints in clinical trials on atrial fibrillation.
Eur Heart J Suppl. 2008;10:H55-78.
APPENDIX 1. CARDIOTHORACIC SURGICAL
TRIALS NETWORK (CTSN)
National Heart, Lung and Blood Institute
Marissa A. Miller, Wendy C. Taddei-Peters, Dennis Bux-
ton, Ron Caulder, Nancy L. Geller, David Gordon, Neal O.
Jeffries, Albert LeeNational Institute of Neurological Disorders and
Stroke
Claudia S. Moyery c August 2011
Gillinov et al Cardiothoracic Surgical Education and TrainingCanadian Institutes of Health Research
Ilana Kogan Gombos, Jennifer RalphE
D
UNetwork Chairs
Christiana Care Health System, Timothy J. Gardner
(chair); Brigham and Women’s Hospital, Patrick T.
O’Gara (co-chair)Data Coordinating Center
International Center for Health Outcomes and Innova-
tion Research (InCHOIR) in the Department of Health
Evidence and Policy, Mount Sinai School of Medicine,
New York, NY, Annetine C. Gelijns, Michael K. Parides,
Deborah D. Ascheim, Alan J. Moskowitz, Ellen Moquete,
Eric A. Rose, Melissa Chase, Yingchun Chen, Rosemarie
Gagliardi, Alejandra Guerchicoff, Lopa Gupta, Alexander
Iribarne, Edlira Kumbarce, Ron Levitan, Karen O’Sullivan,
Mark J. Russo, Milerva Santos, William Slavik, AlanWein-
berg, Martin Wells, Paula Williams, Carrie Wood, Xia YeCore Clinical Site Investigators
Cleveland Clinic Foundation, Eugene H. Blackstone
(principal investigator), A. Marc Gillinov, Tomislav Mihal-
jevic, Richard A. Grimm, Ben Barzilai, Bruce D. Lindsay,
Christine Whitman, Denise Kosty Sweeney, Roberta
Palumbo, NHLBI Clinical Research Scholars Gregory Pat-
takos, Pamela A. Clarke; Columbia University Medical
Center, Michael Argenziano (principal investigator),
MathewWilliams, Lyn Goldsmith, Rebecca T. Hahn, Linda
Gillam, Craig R. Smith, Yoshifumi Naka, Allan Stewart,
Allan Schwartz; Duke University, Peter K. Smith (principal
investigator), StaceyWelsh, John H. Alexander, Carmelo A.
Milano, Donald D. Glower, Joseph P.Mathew, J. Kevin Har-
rison, NHLBI Clinical Research Scholars Mark F. Berry,
Cyrus J. Parsa, Betty C. Tong, Judson B. Williams; East
Carolina Heart Institute, T. Bruce Ferguson (principal
investigator), Alan P. Kypson, Evelio Rodriguez, Malissa
Harris, Brenda Akers, Allison O’Neal; Emory University,
John D. Puskas (principal investigator), Vinod H. Thourani,
Robert Guyton, Jefferson Baer, Kim Baio, Alexis Neill;
Montefiore-Einstein Heart Center, New York, NY, Robert
E. Michler (principal investigator), Ricardo Bello, David
A. D’Alessandro, Joseph J. DeRose, Jr, Daniel J. Goldstein,
Cynthia Taub, Daniel Spevak, Roger Swayze; Montreal
Heart Institute, Louis P. Perrault (principal investigator),
Arsene-Joseph Basmadjian, Denis Bouchard, Michel Car-
rier, Raymond Cartier, Michel Pellerin, Sophie Robichaud;
NIH Heart Center at Suburban Hospital, Keith A. Horvath
(principal investigator), Philip C. Corcoran, Michael P.
Siegenthaler, Mandy Murphy, Margaret Iraola, Ann Green-
berg;University of Pennsylvania,Michael A. Acker (princi-
pal investigator), Y. Joseph Woo, Wilson Y. Szeto, Mary
Lou Mayer; University of Virginia, Irving L. Kron (princi-The Journal of Thoracic and Capal investigator), Gorav Ailawadi, Karen Johnston, John
M. Dent, Sandra Burks, Kim Gahring
Affiliate/Ancillary Sites
Ho^pital du Sacre-Cœur de Montreal, Pierre Page (princi-
pal investigator), Hugues Jeanmart, Philippe Demers,
Claude Sauve, Carole Sirois; Institut Universitaire de Car-
diologie et de Pneumologie de Quebec, Pierre Voisine (prin-
cipal investigator), Franc¸ois Dagenais, Eric Dumont,
Gladys Dussault; Inova Fairfax Hospital, Alan M. Speir
(principal investigator), Niv Ad, Minh Dang; The Ohio
State University Medical Center, Chittoor B. Sai-
Sudhakar (principal investigator), Danielle Jones; WellStar
Health System, Kennestone Hospital, William A. Cooper
(principal investigator), Rajnish Prasad, Richard J. Myung,
Jennifer LaCorte, Melinda Mock
Satellite Sites
Baylor Research Institute,Michael J. Mack (principal in-
vestigator), Robert Smith, William Ryan, Jennifer Withers;
Brigham and Women’s Hospital, Frederick Y. Chen (princi-
pal investigator), R. Morton Bolman III, Anne M. Burgess,
Debra Conboy; Jewish and St. Mary’s Hospital, Mark S.
Slaughter (principal investigator), Matthew Williams, Mar-
cus Stoddard, Heather Moody; Mission Hospital, Mark A.
Groh (principal investigator), Ben Trichon, Todd Hansen,
Claudine Cuento; University of Southern California,
Vaughn A. Starnes (principal investigator), Michael Bowd-
ish, Becky Lopez; University of Maryland, James S. Gam-
mie (principal investigator), Mandeep Mehra, Bartley
Griffith, Dana Beach; Washington University, Ralph J.
Damiano, Jr. (principal investigator), Scott Silvestry, Marc
Moon, Jennifer Lawton
Cardiopulmonary Exercise Core Laboratory
Henry Ford Hospital, Steven J. Keteyian, Clinton A.
Brawner
Echo Core Laboratory
Massachusetts General Hospital, Judy Hung, Xin Zeng
Electrophysiology Core Laboratory
University of Rochester Medical Center, Jean-Philippe
Couderc
Neurocognitive Core Laboratories
Duke University, Joseph P. Mathew
Protocol Review Committee
David A. Bull (chair), Patrice Desvigne-Nickens (execu-
tive secretary), Dennis O. Dixon, Mark Haigney, Richard
Holubkov, Alice Jacobs, Frank Miller, John M. Murkin,
John Spertus, Andrew S. Wechslerrdiovascular Surgery c Volume 142, Number 2 263
Cardiothoracic Surgical Education and Training Gillinov et al
E
D
UData and Safety Monitoring Board
Frank Sellke (chair), Cheryl L.McDonald (executive sec-
retary), Robert Byington, Neal Dickert, Dennis O. Dixon,
John S. Ikonomidis, David O. Williams, Clyde W. Yancy
Medical Monitors
James C. Fang, Wayne Richenbacher
Overall Event Adjudication Committee
Vivek Rao (chair), Karen L. Furie, Rachel Miller, Sean
Pinney, William C. Roberts
Infection Event Adjudication Committee
Rachel Miller (chair); Shirish Huprikar, Marilyn Levi
APPENDIX 2. INCLUSION AND EXCLUSION
CRITERIA
Selected Inclusion Criteria
1. Clinical indications for MVS for the following:
 Organic mitral valve disease, or
 Functional non-ischemic mitral regurgitation, or
 Ischemic mitral regurgitation with evidence of con-
comitant structural mitral valve disease
2a. Persistent AF within 6 months before randomization,
defined as AF that is not self-terminating and lasting
longer than 7 days, or lasting less than 7 days but neces-
sitating pharmacologic or electrical cardioversion.
 Duration of AF documented by medical history and264 The Journal of Thoracic and Cardiovascular Surg Presence of AF documented by a direct electrocardio-
graphicassessmentwithin6monthsbefore randomization
2b. Long-standing persistent AF is defined as continuous
AF greater than 1 year in duration.
 Duration of AF documented by medical history and
 Presence of AF documented by direct electrocardio-
graphic assessment on arrival in the operating roomExclusion Criteria
1. AF without indication for MVS
2. Paroxysmal AF
3. Evidence of left atrial thrombus on intraoperative trans-
esophageal echocardiography
4. Evidence of active infection
5. Mental impairment or other conditions that may not al-
low subject to understand the nature, significance, and
scope of study
6. Surgical management of hypertrophic obstructive car-
diomyopathy
7. Previous catheter ablation for AF
8. Life expectancy of less than 1 year
9. Absolute contraindications for anticoagulation therapy
10. Enrollment in concomitant drug or device trials
11. Uncontrolled hypothyroidism or hyperthyroidism
12. Forced expiratory volume in 1 second less than
30% of predicted value or need for home oxygen
therapyery c August 2011
APPENDIX E1. TREATMENT GUIDELINES
Surgical Ablation and Pacing Procedures
PVI pacing protocol. None of the studies in the literature
assess acute procedural success (conduction block). In the
CTSN trial, a pacing protocol (before and after PVI) con-
firms acute conduction block at the pulmonary vein level.
If the patient presents to the operating room in AF, then after
institution of cardiopulmonary bypass but before cardiople-
gic arrest the surgeon will attempt synchronized cardiover-
sion. If the patient does not present to the operating room in
AF or if cardioversion is successful, pacing threshold for
right and left pulmonary veins will be established and re-
corded. If the patient presents to the operating room in
AF and cardioversion is unsuccessful, the pacing protocol
will not be attempted, and the surgeon will conduct ablation
according to the lesion set specified. In such instances, we
recommend that bipolar ablation devices be applied 3 times
and unipolar devices be applied 1 time in performing PVI.
This pacing protocol will be followed for all patients after
completion of the ablation procedure.
Pulmonary vein isolation. Bipolar energy sources are pre-
ferred for PVI alone and for the PVI component of the biatrial
maze lesion set. For PVI, 2 separate encircling lesions will be
made around left and right pulmonary veins (Figure 2). The
right pulmonary veins will be isolated first. Isolation will be
confirmed by pacing the pulmonary veins at the previously
identified threshold for capture. If no atrial capture is noted,
it will be inferred that the right pulmonary veins have been
isolated. If atrial capture is observed, additional ablations on
the atrial cuff will be performed until isolation is confirmed.
This protocol will be repeated for left PVI. For PVI with uni-
polar energy sources, a box lesion will bemade, consisting of
a continuous ablation line around all 4 pulmonary veins.
Biatrial maze lesion set. After PVI, the heart will be ar-
rested and the LAA excised or excluded. The remainder
of the procedure for patients randomly allocated to the bia-
trial maze lesion set will be performed at a point in the op-
eration dictated by the surgeon’s standard practice.
Components will include the following:
 Left atriotomy: The left atrium will be opened adjacent to
the interatrial groove, anterior to the right pulmonary veins.
 Connecting lesions from right to left pulmonary veins: A
bipolar device will be used to create separate lesions be-
tween superior pulmonary veins and between inferior
pulmonary veins, or a unipolar device will be used to en-
circle all 4 veins (box lesion).
 Connecting lesion to mitral annulus: A cryosurgical de-
vice or unipolar heat-based device will be used to create
a connection from the box lesion to the mitral annulus.
This lesion will be directed toward the P3 segment of
the mitral valve.
 Connecting lesion to left atrial appendage: After exci-
sion or exclusion of the LAA (see following text),
a unipolar or bipolar energy source will be used to create
a connecting lesion from its orifice to the box lesion.
 Right atrial lesions: A vertical right atriotomy will be
made beginning from the atrioventricular groove and ex-
tending toward the fossa ovalis. A unipolar energy source
will be used to connect this lesion to the tricuspid annulus
at the 2 o’clock position as viewed by the surgeon (A in
Figure E1). A unipolar or bipolar energy source will be
used to connect the posterior aspect of this atriotomy to
the superior and inferior venae cavae (B in Figure E1).
An incision will be made in the body of the right atrial ap-
pendage, and a unipolar energy sourcewill be used to con-
nect the incision to the tricuspid annulus at the 10 o’clock
position as viewed by the surgeon (C in Figure E1). At the
discretion of the surgeon, patients with a history of atrial
flutter are candidates for the right atrial isthmus lesion.
Energy Sources
In recent years, several energy sources for ablation have
been introduced into clinical practice. There do not appear
to be significant differences in efficacy or safety of different
energy sources. Radiofrequency ablation is the oldest and
most extensively studied mode of ablation in the literature
at this time. Given the fact that radiofrequency is the en-
ergy source with the largest clinical experience, results
from a trial that does not incorporate radiofrequency
ablation may lack generalizability to the broader surgical
community. In this trial, we limited the number of devices
with a radiofrequency energy source, including both bipo-
lar and unipolar devices. In addition to the linear lesions
created by unipolar or bipolar radiofrequency, additional
spot lesions will be created at the mitral annulus and isth-
mus with either unipolar radiofrequency or cryotherapy.
The cryoprobe is recommended for creating lesions near
the mitral or tricuspid annulus; this enables incorporation
of the coronary sinus. As such, this trial does not evaluate
any specific device but rather a therapeutic approach,
which is distinct from most industry-sponsored trials of
new devices.
LAA Closure or Exclusion
Closure (amputation) of the LAA may be achieved by
cut-and-sew technique or by application of a surgical
stapler. Exclusion of the LAA may be accomplished by
oversewing or stapling across its base.
Follow-up Medical Management
Unless contraindicated (hypotension or bradycardia with
heart rate<60 beats/min), all patients will receive prophy-
lactic class I or III antiarrhythmic drugs (amiodarone,
sotalol, propafenone, procainamide) beginning within 24
hours of surgery and will be discharged while still receiving
the agent. At 3 months, antiarrhythmic agents will be
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FIGURE E1. Right atrial lesions.
terminated in all patients, and this recommendation will be
communicated to the managing physician. Direct current
cardioversion will be performed by managing physicians
as clinically indicated. Unless contraindicated, warfarin
sodium is prescribed for patients in both arms throughout
the follow-up period.
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